Media stories about Concord Medical Services (NYSE:CCM) have been trending somewhat positive on Thursday, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Concord Medical Services earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned news stories about the company an impact score of 48.3322770685866 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Separately, Zacks Investment Research upgraded shares of Concord Medical Services from a “sell” rating to a “hold” rating in a report on Tuesday, July 3rd.
CCM stock traded up $0.10 during mid-day trading on Thursday, reaching $2.99. 700 shares of the stock traded hands, compared to its average volume of 2,518. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.10 and a quick ratio of 1.00. Concord Medical Services has a 52 week low of $2.46 and a 52 week high of $4.20. The stock has a market capitalization of $150.91 million, a price-to-earnings ratio of -2.93 and a beta of 0.78.
Concord Medical Services Company Profile
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company's services comprise linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, CyberKnife robotic radiosurgery system, proton beam therapy systems, and diagnostic imaging services.
Receive News & Ratings for Concord Medical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concord Medical Services and related companies with MarketBeat.com's FREE daily email newsletter.